News

The World Health Organization (WHO) Technical Advisory Group on Virus Evolution (TAG-VE) yesterday published a detailed risk ...
Positive provider attitude and self-efficacy toward screening, larger institution size, recent training, and college policy ...
The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.
(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.
Wall Street surged as the S&P 500 reclaimed 6,000, fueled by a strong jobs report. Discover market movers like Tesla, Moderna, and Procter & Gamble.
The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.
The product is a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years.
HHS Secretary Robert F. Kennedy Jr. says Moderna (MRNA) has agreed to do another clinical trial to back its newly approved ...
Moderna MRNA announced the FDA approval for mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, though for a ...
The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement ...
Ga., slammed the U.S. Food and Drug Administration's move to give the green light to Moderna's mNEXSPIKE COVID-19 vaccine.
From eligibility to dosage and future rollout, here’s what you need to know about the FDA’s latest vaccine approval.